Ekso Financial Statements From 2010 to 2026

EKSO Stock

USD 11.16 1.29 13.07%

Ekso Bionics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Ekso Bionics' valuation are provided below:

Gross Profit

7.9 M

Profit Margin

(0.71)

Market Capitalization

39.7 M

Enterprise Value Revenue

2.5346

Revenue

14.7 M

We have found one hundred twenty available fundamental signals for Ekso Bionics Holdings, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Ekso Bionics' prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 18th of February 2026, Market Cap is likely to drop to about 252.8 M. In addition to that, Enterprise Value is likely to drop to about 238.5 M

Ekso Bionics Total Revenue

11.51 Million

Check Ekso Bionics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ekso Bionics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 260.2 K or Selling General Administrative of 9.2 M, as well as many indicators such as Price To Sales Ratio of 11.24, Dividend Yield of 0.0076 or PTB Ratio of 15.86. Ekso financial statements analysis is a perfect complement when working with Ekso Bionics Valuation or Volatility modules.

Build AI portfolio with Ekso Stock

Check out the analysis of Ekso Bionics Correlation against competitors.

Ekso Bionics Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

26.2 M

30.6 M

23 M

Slightly volatile

Short and Long Term Debt Total

5.1 M

6.9 M

4.5 M

Slightly volatile

Total Current Liabilities

6.7 M

8.7 M

5.9 M

Slightly volatile

Total Stockholder Equity

13.7 M

14.6 M

11.2 M

Slightly volatile

Property Plant And Equipment Net

2.6 M

2.7 M

2.3 M

Slightly volatile

Accounts Payable

2.3 M

1.8 M

2 M

Slightly volatile

Cash

7.1 M

7.5 M

12.4 M

Pretty Stable

Non Current Assets Total

5 M

9 M

4.6 M

Slightly volatile

Cash And Short Term Investments

7.1 M

7.5 M

12.4 M

Pretty Stable

Common Stock Total Equity

8.7 K

9.2 K

30.6 K

Pretty Stable

Liabilities And Stockholders Equity

26.2 M

30.6 M

23 M

Slightly volatile

Non Current Liabilities Total

7.4 M

6 M

Slightly volatile

Inventory

2.7 M

5.3 M

2.5 M

Slightly volatile

Other Stockholder Equity

177.8 M

301.5 M

152.4 M

Slightly volatile

Total Liabilities

13.6 M

16 M

11.9 M

Slightly volatile

Total Current Assets

22 M

21.7 M

19.1 M

Slightly volatile

Short Term Debt

1.1 M

1.9 M

1 M

Slightly volatile

Common Stock

32.1 K

19.8 K

34.4 K

Very volatile

Common Stock Shares Outstanding

24.3 M

23.2 M

7.6 M

Slightly volatile

Net Receivables

8.7 M

8.3 M

3.6 M

Slightly volatile

Other Current Assets

769.4 K

486.9 K

1.1 M

Slightly volatile

Other Liabilities

1.2 M

1.3 M

4 M

Slightly volatile

Net Tangible Assets

15.5 M

22.8 M

17.4 M

Very volatile

Long Term Debt

3.8 M

4.4 M

2.8 M

Slightly volatile

Long Term Debt Total

11 M

10.5 M

5.4 M

Slightly volatile

Capital Surpluse

165 M

235 M

155.6 M

Slightly volatile

Deferred Long Term Liabilities

30.8 K

32.4 K

1.4 M

Slightly volatile

Property Plant And Equipment Gross

3.3 M

6.6 M

3 M

Slightly volatile

Short and Long Term Debt

1.7 M

1.1 M

1.5 M

Slightly volatile

Intangible Assets

2.8 M

5.3 M

2.8 M

Slightly volatile

Property Plant Equipment

2.6 M

4.6 M

2.6 M

Slightly volatile

Non Current Liabilities Other

154.8 K

162.9 K

552.4 K

Slightly volatile

Deferred Long Term Asset Charges

2 M

2.3 M

2.5 M

Slightly volatile

Capital Lease Obligations

693.7 K

1 M

453.2 K

Slightly volatile

Net Invested Capital

22 M

20.5 M

23.6 M

Slightly volatile

Net Working Capital

14.1 M

10.2 M

20.3 M

Slightly volatile

Capital Stock

25.3 K

19.8 K

45.3 K

Slightly volatile

Ekso Bionics Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Depreciation And Amortization

1.1 M

1.8 M

989.4 K

Slightly volatile

Selling General Administrative

9.2 M

10.1 M

8 M

Slightly volatile

Selling And Marketing Expenses

9.6 M

8.4 M

8.5 M

Slightly volatile

Total Revenue

11.5 M

20.6 M

10.2 M

Slightly volatile

Gross Profit

11.5 M

10.9 M

4.7 M

Slightly volatile

Other Operating Expenses

30.1 M

32.6 M

26.6 M

Slightly volatile

Research Development

4.1 M

3.5 M

5.1 M

Slightly volatile

Cost Of Revenue

6.7 M

9.7 M

5.9 M

Slightly volatile

Total Operating Expenses

23.6 M

23 M

20.9 M

Slightly volatile

Non Recurring

482 K

389.7 K

539.7 K

Slightly volatile

Reconciled Depreciation

889.4 K

1.4 M

Slightly volatile

Ekso Bionics Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Begin Period Cash Flow

16.2 M

9.9 M

12.8 M

Slightly volatile

Total Cash From Financing Activities

12.3 M

7 M

12.9 M

Very volatile

End Period Cash Flow

7.1 M

7.5 M

12.4 M

Pretty Stable

Stock Based Compensation

2.6 M

1.9 M

2.1 M

Slightly volatile

Depreciation

1.3 M

1.8 M

1.1 M

Slightly volatile

Dividends Paid

8.3 M

9.3 M

10.2 M

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

11.24

11.84

149

Slightly volatile

Dividend Yield

0.0076

0.0086

0.0094

Slightly volatile

PTB Ratio

15.86

16.7

311.8 K

Slightly volatile

Days Sales Outstanding

91.5

133

107

Slightly volatile

Book Value Per Share

0.69

0.72

4.6668

Slightly volatile

Average Payables

1.3 M

1.5 M

1.6 M

Slightly volatile

Stock Based Compensation To Revenue

0.0993

0.1

0.2041

Slightly volatile

Capex To Depreciation

0.0251

0.0265

0.7766

Slightly volatile

PB Ratio

15.86

16.7

311.8 K

Slightly volatile

EV To Sales

11.21

11.8

148

Slightly volatile

Inventory Turnover

3.69

2.12

3.4814

Slightly volatile

Days Of Inventory On Hand

118

178

140

Slightly volatile

Payables Turnover

5.12

4.88

3.1636

Slightly volatile

Sales General And Administrative To Revenue

0.96

0.56

0.9331

Slightly volatile

Average Inventory

536.1 K

603.2 K

658.4 K

Slightly volatile

Research And Ddevelopement To Revenue

0.24

0.25

0.7315

Slightly volatile

Capex To Revenue

0.0023

0.0024

0.1037

Slightly volatile

Cash Per Share

0.35

0.37

6.2348

Slightly volatile

Days Payables Outstanding

73.55

77.42

140

Slightly volatile

Income Quality

0.73

0.78

0.8734

Very volatile

Intangibles To Total Assets

0.18

0.17

0.0757

Slightly volatile

Net Debt To EBITDA

0.0461

0.0486

0.6207

Very volatile

Current Ratio

2.49

2.25

2.9811

Pretty Stable

Tangible Book Value Per Share

0.42

0.44

4.4012

Slightly volatile

Receivables Turnover

3.99

2.85

3.877

Slightly volatile

Shareholders Equity Per Share

0.69

0.72

4.6668

Slightly volatile

Debt To Equity

0.51

0.54

1.6893

Slightly volatile

Capex Per Share

0.002

0.0021

0.5921

Slightly volatile

Revenue Per Share

0.97

1.02

4.7228

Slightly volatile

Interest Debt Per Share

0.34

0.36

0.9017

Very volatile

Debt To Assets

0.22

0.26

0.2044

Pretty Stable

Operating Cycle

203

311

239

Slightly volatile

Price Book Value Ratio

15.86

16.7

311.8 K

Slightly volatile

Days Of Payables Outstanding

73.55

77.42

140

Slightly volatile

Ebt Per Ebit

1.14

1.25

1.1728

Slightly volatile

Effective Tax Rate

0.0352

0.0396

0.0432

Slightly volatile

Company Equity Multiplier

2.29

2.41

5.2728

Slightly volatile

Long Term Debt To Capitalization

0.4

0.27

0.383

Slightly volatile

Total Debt To Capitalization

0.39

0.37

0.364

Pretty Stable

Debt Equity Ratio

0.51

0.54

1.6893

Slightly volatile

Cash Ratio

0.94

0.99

2.1441

Pretty Stable

Days Of Inventory Outstanding

118

178

140

Slightly volatile

Days Of Sales Outstanding

91.5

133

107

Slightly volatile

Free Cash Flow Operating Cash Flow Ratio

1.13

1.15

1.0568

Pretty Stable

Price To Book Ratio

15.86

16.7

311.8 K

Slightly volatile

Fixed Asset Turnover

3.66

6.82

4.3644

Slightly volatile

Debt Ratio

0.22

0.26

0.2044

Pretty Stable

Price Sales Ratio

11.24

11.84

149

Slightly volatile

Asset Turnover

0.73

0.77

44.7414

Slightly volatile

Gross Profit Margin

0.3

0.48

0.3522

Slightly volatile

Price Fair Value

15.86

16.7

311.8 K

Slightly volatile

Ekso Bionics Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

252.8 M

266.1 M

647.5 M

Slightly volatile

Enterprise Value

238.5 M

251.1 M

635 M

Slightly volatile

Ekso Fundamental Market Drivers

Ekso Upcoming Events

	26th of March 2024 Upcoming Quarterly Report	View
	25th of April 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	26th of March 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Ekso Bionics Financial Statements

Ekso Bionics investors utilize fundamental indicators, such as revenue or net income, to predict how Ekso Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Current Deferred Revenue	2.2 M	1.4 M
Total Revenue	20.6 M	11.5 M
Cost Of Revenue	9.7 M	6.7 M
Stock Based Compensation To Revenue	0.10	0.10
Sales General And Administrative To Revenue	0.56	0.96
Research And Ddevelopement To Revenue	0.25	0.24
Revenue Per Share	1.02	0.97
Ebit Per Revenue	(0.53)	(0.55)

Pair Trading with Ekso Bionics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ekso Bionics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ekso Bionics will appreciate offsetting losses from the drop in the long position's value.

Moving against Ekso Stock

0.87	ELAB	Elevai Labs Common	Pair Corr
0.74	IPD	Impedimed Earnings Call This Week	Pair Corr
0.72	OTC	Ocumetics Technology Corp	Pair Corr
0.64	EW	Edwards Lifesciences Corp	Pair Corr
0.63	DYNT	Dynatronics	Pair Corr

The ability to find closely correlated positions to Ekso Bionics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ekso Bionics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ekso Bionics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ekso Bionics Holdings to buy it.

The correlation of Ekso Bionics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ekso Bionics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ekso Bionics Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Ekso Bionics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Ekso Bionics Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ekso Bionics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ekso Bionics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ekso Bionics Holdings Stock:

How To Invest In Ekso

Details

Is Ekso Stock a good investment?

Details

What is Ekso Bionics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out the analysis of Ekso Bionics Correlation against competitors.

You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Will Health Care Equipment & Supplies sector continue expanding? Could Ekso diversify its offerings? Factors like these will boost the valuation of Ekso Bionics. Projected growth potential of Ekso fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ekso Bionics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Earnings Share

(6.13)

Revenue Per Share

7.246

Quarterly Revenue Growth

0.024

Return On Assets

(0.27)

Return On Equity

(0.85)

Investors evaluate Ekso Bionics Holdings using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Ekso Bionics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Ekso Bionics' market price to deviate significantly from intrinsic value.

It's important to distinguish between Ekso Bionics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Ekso Bionics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Ekso Bionics' market price signifies the transaction level at which participants voluntarily complete trades.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Ekso Financial Statements From 2010 to 2026

Ekso Bionics Total Revenue

11.51 Million

Ekso Bionics Balance Sheet

Ekso Bionics Income Statement

Ekso Bionics Cash Flow Statement

Financial Ratios

Ekso Bionics Valuation Data

Ekso Fundamental Market Drivers

Ekso Upcoming Events

About Ekso Bionics Financial Statements

Pair Trading with Ekso Bionics

Moving against Ekso Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY